Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement.

The proposal includes a 30-day option for initial buyers to purchase up to an additional $50 million aggregate principal amount under the same terms.

The stock was down 4.27% to $6.72 at 4:46 p.m.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ARIA Price Chart

ARIA Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)